Advertisement

Tumor Necrosis Treatment and Imaging of Solid Tumors

  • Alan L. Epstein
  • Leslie A. Khawli
  • Peisheng Hu
Chapter

Abstract

A novel approach to cancer imaging and therapy utilizing necrotic cells as targets for the selective binding of monoclonal antibodies has been developed in our laboratory. Tumor Necrosis Therapy (TNT) represents a radical departure from current methods that employ monoclonal antibodies (MAbs) to bind to tumor-associated cell surface antigens and require the use of different antibodies for each type of tumor. In contrast, TNT is based upon the hypothesis that MAbs against intracellular antigens that are found in all cells and are retained by dying cells show preferential localization in malignant tumors due to the presence of abnormally permeable, degenerating cells not found in normal tissues. It has long been recognized that rapidly dividing tumors contain a proportion of degenerating or dead cells, but, with attention focused upon attempts to kill the dividing cells, the degenerating component has largely been ignored. Calculations of tumor cell loss have revealed that, in contrast to normal tissues, 30–80% of the progeny of tumor cell divisions shortly undergo degeneration. In tumors, the imperfect vasculature and impaired phagocytic response permit the accumulation of degenerating cells, often with the formation of large areas of necrosis, long recognized by pathologists to be a typical feature of malignant tumors. Thus, the accumulation within tumors of a high proportion of dying cells constitutes a major distinction between malignant tumors and normal tissues, where sporadic cell death occurs at a relatively low rate and is accompanied by a rapid and orderly removal of necrotic elements from the tissue. Since degenerating cells have permeable cell surface membranes not observed in viable cells, TNT MAbs enter and bind to their intracellular antigens in necrotic areas of the tumor. Contrarily, TNT antibodies diffusing in viable regions of the tumor and normal tissues do not bind and are removed from the circulation by normal clearance mechanisms. Hence, TNT provides a novel approach for specifically targeting necrotic regions of tumors and can be used to deliver diagnostic and therapeutic reagents into the central core of tumors.

Keywords

Tumor Uptake Necrotic Region Complementary Determine Region Therapeutic Reagent Biomedical Aspect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kemshead J, Hopkins K. Uses and limitations of monoclonal antibodies in the treatment of malignant disease: A review. Diagnostic Oncology 1993; 2: 219–224.Google Scholar
  2. 2.
    Epstein AL, Chen F-M, Taylor CR. A Novel Method for the Detection of Necrotic Lesions in Human Cancers. Cancer Research 1988; 48: 5842–5848.Google Scholar
  3. 3.
    Miller GK, Naeve GS, Gaffar SA, Epstein AL. Immunologic and biochemical analysis of TNT-1 and TNT-2 monoclonal antibody binding to histones. Hybridoma 1993; 12: 689–698.CrossRefGoogle Scholar
  4. 4.
    Hornick JL, Hu P, Khawli LA, Biela BH, Yun A, Sharifi J, et al. chTNT-3/B, a new chemically modified chimeric monoclonal antibody directed against DNA for the tumor necrosis treatment of solid tumors. Cancer Biotherapy and Radiopharmaceuticals 1998; 13 (4): 255–268.CrossRefGoogle Scholar
  5. 5.
    Jones ST, Bendig MM. Rapid PCR-cloning of full-length mouse immunoglobulin variable regions. Bio/Technology 1991; 9: 88–89.CrossRefGoogle Scholar
  6. 6.
    Winter G, Harris WJ. Humanized antibodies (review). Trends in Pharmacolog. Sci. 1993; 14: 139–143.Google Scholar
  7. 7.
    Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By- passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 1991; 222: 581–597.CrossRefGoogle Scholar
  8. 8.
    Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1998; 59: 1236–1243.Google Scholar
  9. 9.
    Karpas A, Dremucheva A, Czepulkowski BH. A human myeloma cel line suitable for the generation of human monoclonal antibodies. Proc Natl Acad Sci U S A 2001; 98: 1799–1804.CrossRefGoogle Scholar
  10. 10.
    Sharifi J, Khawli LA, Hu P, King S, Epstein AE. Characterization of a Phage Display-Derived Human Monoclonal Antibody (NHS76) Counterpart to Chimeric TNT-1 Directed Against Necrotic Regions of Solid Tumors. Hybridoma and Hybridomics 2001; 20 (5): 305–312.CrossRefGoogle Scholar
  11. 11.
    Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, et al. Human antibodies with subnanomolar affinities isolated from a large non-immunized phage display library. Nature Biotechnology 1996; 14: 309–314.CrossRefGoogle Scholar
  12. 12.
    Hornick JL, Sharifi J, Khawli LA, Hu P, Biela BH, Mizokami MM, et al. A new chemically modified chimeric TNT-3 monoclonal antibody directed against DNA for the radioimmunotherapy of solid tumors. Cancer Biotherapy Radiopharmaceuticals 1998; 13 (4): 255–268.CrossRefGoogle Scholar
  13. 13.
    Chen F-M, Epstein AL, Li Z, Taylor CR. A comparative autoradiographic study demonstrating differential intratumor localization of monoclonal antibodies to cell surface (Lym-1) and intracellular (TNT-1) antigens. Journal of Nuclear Medicine 1990; 31: 1059–1066.Google Scholar
  14. 14.
    Larsen SM. Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy. J. Nucl. Med. 1985; 26: 538–550.Google Scholar
  15. 15.
    Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of single- chain Fv and comparison with other immunoglobulin forms. Cancer Research 1992; 52: 3402–3410.Google Scholar
  16. 16.
    Hudson PJ, Kortt AA. High avidity scFv multimers, diabodies and triabodies. J. Immunological Methods 1999; 231: 177–189.CrossRefGoogle Scholar
  17. 17.
    Holliger P, Prospero T, Winter G. Diabodies: Small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A 1993; 90: 6444–6448.CrossRefGoogle Scholar
  18. 18.
    Whitlow M, Filpula D, Rollence ML, Feng S-L, Woods JF. Multivalent Fvs: characterization of single chain Fv oligomers and preparation of bispecific Fv. Protein Engineering 1994; 7: 1017–1026.CrossRefGoogle Scholar
  19. 19.
    Khawli LA, Biela BH, Hu P, Epstein AL. Stable, genetically engineered F(ab’)2 fragments of chimeric TNT-3 expressed in mammalian cells. Hybidoma and Hybridomics 2002; 21 (1): 11–18.CrossRefGoogle Scholar
  20. 20.
    Verma R, Boleti E, George AJT. Antibody engineering: Comparison of bacterial, yeast, insect, and mammalian expression systems. J. Immunol. Methods 1998; 216: 165–181.CrossRefGoogle Scholar
  21. 21.
    Milenic DE, Yokota T, Filpula DR, Finkelman MAJ, Dodd SW, Wood JF, et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Research 1991; 51: 6363–6371.Google Scholar
  22. 22.
    Adams GP, Schier R. Generating improved single-chain Fv molecules for tumor targeting. J. Immunol. Methods 1999; 231: 249–260.CrossRefGoogle Scholar
  23. 23.
    Kang N, Hamilton S, Odili J, Wilson G, Kupsch J. In vivo targeting of malignant melanoma by 125iodine-and 99mTc-labeled single-chain Fv fragments against high molecular weight melanoma-associated antigens. Clin. Cancer Res. 2000; 6: 4921–4931.Google Scholar
  24. 24.
    Hornick JL, Sharifi J, Khawli LA, Hu P, Bai WG, Alauddin MM, et al. Single Amino Acid Substitution in the Fc Region of Chimeric TNT-3 Antibody Accelerates Clearance and Improves Immunoscintigraphy of Solid Tumors. Journal of Nuclear Medicine 2000; 41: 355–362.Google Scholar
  25. 25.
    Khawli LA, Glasky MS, Alauddin MM, Epstein AL. Improved tumor localization and radioimaging with chemically modified monoclonal antibodies. Cancer Biotherapy Radiopharmaceuticals 1996; 11: 203–215.CrossRefGoogle Scholar
  26. 26.
    LeBerthon B, Khawli LA, Alauddin M, Miller GK, Charak BS, Mazumder A, et al. Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Research 1991; 51: 2694–2698.Google Scholar
  27. 27.
    Khawli LA, Miller GK, Epstein AL. Effect of seven new vasoactive immunoconjugates on the enhancement of monoclonal antibody uptake in tumors. Cancer 1994; 73: 824–831.CrossRefGoogle Scholar
  28. 28.
    Hornick JL, Khawli LA, Hu P, Sharifi J, Khanna C, Epstein AL. Pretreatment with a Monoclonal Antibody/Interleukin-2 Fusion Protein Directed against DNA Enhances the Delivery of Therapeutic Molecules to Solid Tumors. Clinical Cancer Research 1999; 5: 51–60.Google Scholar
  29. 29.
    Rosenstein M, Ettinghausen SE, Rosenberg SA. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. Immunology 1986; 137: 1735–1742.Google Scholar
  30. 30.
    Epstein AL, Khawli LA, Hornick JL, Taylor CR. Identification of a Monoclonal Antibody, TV-1, Directed against the Basement Membrane of Tumor Vessels, and Its Use to Enhance the Delivery of Macromolecules to Tumors after Conjugation with Interleukin-2. Cancer Res. 1995; 55: 2673–2680.Google Scholar
  31. 31.
    Goldrosen MH, Biddle WC, Pancook J, Bakshi S, Vanderheyden J-L, Fritzberg AR, et al. Biodistribution, pharmacokinetic, and imaging studies with 186Re-labeled NRLU-10 whole antibody in LS174T colonic tumor-bearing mice. Cancer Research 1990; 50: 7973–7978.Google Scholar
  32. 32.
    Breitz HB, Sullivan K, Nelp WB. Imaging lung cancer with radiolabeled antibodies. Seminars in Nuclear Medicine 1993; 23: 127–132.CrossRefGoogle Scholar
  33. 33.
    Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC. Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E1105. Cancer Research 1990; 50: 6423–6429.Google Scholar
  34. 34.
    Chengazi VU, Feneley MR, Ellison D, Stalteri M, Granowski A, Granowska M, et al. Imaging prostate cancer with technetium-99m-7E11–05.3 (CYT-351). Journal of Nuclear Medicine 1997; 38: 675–682.Google Scholar
  35. 35.
    Epstein AL, Mizokami MM, Hu P, Khawli LA. Permeability enhancing peptide (PEP): A protein fragment of IL-2 responsible for vasopermeability and useful in the generation of agents to increase the effectiveness of chemotherapy. Nature Biotechnology in press.Google Scholar
  36. 36.
    Marks TA, Woodman RJ, Geran RI, Billups LH, Madison RM. Characterization and Responsiveness of the Madison 109 Lung Carcinoma to Various Antitumor Agents. Cancer Treatment Reports 1977; 61 (8): 1459–1470.Google Scholar
  37. 37.
    Rose WC. Evaluation of Madison 109 Lung Carcinoma as a Model for Screening Antitumor Drugs. Cancer Treatment Reports 1981; 65 (3–4): 299–312.Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Alan L. Epstein
    • 1
  • Leslie A. Khawli
    • 1
  • Peisheng Hu
    • 1
  1. 1.Department of PathologyKeck School of Medicine at the University of Southern CaliforniaLos AngelesUSA

Personalised recommendations